LT3076949T - Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas - Google Patents

Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas

Info

Publication number
LT3076949T
LT3076949T LT14867768T LT14867768T LT3076949T LT 3076949 T LT3076949 T LT 3076949T LT 14867768 T LT14867768 T LT 14867768T LT 14867768 T LT14867768 T LT 14867768T LT 3076949 T LT3076949 T LT 3076949T
Authority
LT
Lithuania
Prior art keywords
exoxomes
derived
cancer cell
isolating cancer
isolating
Prior art date
Application number
LT14867768T
Other languages
English (en)
Inventor
Raghu Kalluri
Sonia Melo
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of LT3076949T publication Critical patent/LT3076949T/lt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
LT14867768T 2013-12-04 2014-12-04 Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas LT3076949T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911863P 2013-12-04 2013-12-04
PCT/US2014/068630 WO2015085096A1 (en) 2013-12-04 2014-12-04 Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis

Publications (1)

Publication Number Publication Date
LT3076949T true LT3076949T (lt) 2019-12-10

Family

ID=53274132

Family Applications (1)

Application Number Title Priority Date Filing Date
LT14867768T LT3076949T (lt) 2013-12-04 2014-12-04 Iš vėžinių ląstelių kilusių egzosomų išskyrimo būdas

Country Status (13)

Country Link
US (3) US9921223B2 (lt)
EP (1) EP3076949B1 (lt)
JP (3) JP2017501694A (lt)
AU (3) AU2014360344B2 (lt)
CA (1) CA2936100A1 (lt)
DK (1) DK3076949T3 (lt)
HR (1) HRP20192131T1 (lt)
HU (1) HUE046489T2 (lt)
LT (1) LT3076949T (lt)
NZ (1) NZ721720A (lt)
SI (1) SI3076949T1 (lt)
WO (1) WO2015085096A1 (lt)
ZA (1) ZA201604468B (lt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US9599611B2 (en) 2005-04-25 2017-03-21 Trustees Of Boston University Structured substrates for optical surface profiling
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
PT3527670T (pt) 2013-03-15 2024-01-18 Beth Israel Deaconess Medical Ct Inc Biogénese de mirna em exossomas para diagnóstico e terapia
HUE046489T2 (hu) * 2013-12-04 2020-03-30 Univ Texas Eljárás ráksejtekbõl származó exoszómák izolálására
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
CR20160307A (es) 2013-12-20 2016-11-08 Advanced Regen Medical Tech Llc Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
US10844436B2 (en) * 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
WO2016172710A2 (en) 2015-04-24 2016-10-27 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
US11339441B2 (en) * 2015-05-12 2022-05-24 The Research Foundation For The State University Of New York Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
AU2016276750A1 (en) 2015-06-09 2018-01-18 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
IL256175B2 (en) 2015-06-10 2024-10-01 Univ Texas Using exosomes to treat the disease
EP3353528B1 (en) 2015-09-22 2023-11-29 Trustees of Boston University Multiplexed phenotyping of nanovesicles
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
EP3411713B1 (en) 2016-02-05 2021-06-30 NanoView Biosciences, Inc. Detection of exosomes having surface markers
SG10202008883SA (en) * 2016-03-15 2020-10-29 Codiak Biosciences Inc Therapeutic membrane vesicles
WO2017190000A1 (en) 2016-04-29 2017-11-02 Advanced ReGen Medical Technologies, LLC Microrna compositions and methods of making and using same
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US20190234955A1 (en) * 2016-06-21 2019-08-01 Nant Holdings Ip, Llc Exosome-guided treatment of cancer
CN106124282B (zh) 2016-07-26 2019-07-16 广州海力特生物科技有限公司 一种叠层离心过滤分离提取外泌体的方法
US20180067121A1 (en) * 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
WO2018173059A1 (en) 2017-03-21 2018-09-27 Exoprother Medical Ltd. Native cell derived vesicles containing tumor suppressor proteins for therapy
GB2560897A (en) * 2017-03-23 2018-10-03 Lotvall Jan Tissue-derived extracellular vesicles and their use as diagnostics
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107338306A (zh) * 2017-07-23 2017-11-10 嘉兴允英医学检验有限公司 一种用于GPC1mRNA表达检测的试剂盒
WO2019028223A1 (en) * 2017-08-04 2019-02-07 Cedars-Sinai Medical Center CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR THE TREATMENT AND PREVENTION OF CANCER
WO2019191444A1 (en) * 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of exosomes for targeted delivery of therapeutic agents
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
CN111566484A (zh) 2017-11-09 2020-08-21 宾夕法尼亚大学董事会 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途
CN111971560B (zh) 2017-12-01 2024-06-11 康奈尔大学 用于检测和治疗癌症的纳米颗粒和不同的外泌体子集
WO2019118826A1 (en) 2017-12-15 2019-06-20 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using exosomes-associated gene editing
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
KR20200108275A (ko) * 2017-12-28 2020-09-17 코디악 바이오사이언시즈, 인크. 면역-종양학 및 항-염증 요법을 위한 엑소좀
US10717981B2 (en) 2018-01-18 2020-07-21 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
WO2019178317A1 (en) 2018-03-14 2019-09-19 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
AU2019242912B2 (en) * 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
US20210024936A1 (en) * 2018-04-09 2021-01-28 Board Of Regents, The University Of Texas System Therapeutic targeting of oncogenes using exosomes
CA3099385A1 (en) * 2018-05-04 2019-11-07 Sigma-Aldrich Co. Llc Producing recombinant proteins with reduced levels of host cell proteins
US12510462B2 (en) 2018-06-01 2025-12-30 Unchained Labs Compositions, systems, and methods for enhanced label-free and fluorescence-based detection of nanoparticles
IL269897B2 (en) 2018-11-15 2023-08-01 Sternum Ltd Implementing control flow correctness verification in code intermediate files
US11766484B2 (en) 2019-01-03 2023-09-26 International Business Machines Corporation Exosome vessels for delivery of molecular cargo
EP3908262A4 (en) 2019-01-09 2022-12-28 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
US20220113313A1 (en) * 2019-02-01 2022-04-14 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
KR20210125532A (ko) * 2019-02-08 2021-10-18 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 진단 및 치료 목적을 위한 엑소좀 관련 마이크로바이옴의 단리 및 검출
US12502427B2 (en) * 2019-03-21 2025-12-23 Lonza Sales Ag Extracellular vesicles for vaccine delivery
CA3137525A1 (en) * 2019-04-23 2020-10-29 Children's Medical Center Corporation Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb)
US20230313147A1 (en) * 2019-06-04 2023-10-05 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold plasma treatment mediated mutant specific t cell immunity
US12564608B2 (en) 2019-09-13 2026-03-03 Exocure Sweden Ab Use of ghost nanovesicles as therapeutics
JP7462452B2 (ja) * 2020-03-27 2024-04-05 株式会社日立製作所 培養細胞の分化レベルを評価するための評価装置および評価方法、並びに自動細胞培養システム
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
US20230340606A1 (en) * 2021-09-09 2023-10-26 The Regents Of The University Of California Extracellular repetitive rna biomarkers of mutant kras cancers
US20250011876A1 (en) * 2021-11-02 2025-01-09 The Regents Of The University Of California Extracellular rna signatures of mutant kras(g12c) cancers
WO2023210644A1 (ja) * 2022-04-26 2023-11-02 国立大学法人東京大学 がん細胞由来細胞外小胞群の単離濃縮方法、分析方法、薬剤選択方法、キット、及び抗がん剤
US20250290919A1 (en) * 2022-05-06 2025-09-18 The Trustees Of The University Of Pennsylvania Ultrasensitive single extracellular vesicle detection using high throughput droplet digital enzyme-linked immunosorbent assay
WO2024047441A1 (en) * 2022-09-01 2024-03-07 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Method for monitoring tumor burden in subjects during therapeutic intervention
US20260100247A1 (en) * 2022-09-30 2026-04-09 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20030064949A1 (en) 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
ES2936256T3 (es) * 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
US20120196285A1 (en) * 2011-01-31 2012-08-02 Esoterix Genetic Laboratories, Llc Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
US9309559B2 (en) * 2013-04-15 2016-04-12 Albert Einstein College Of Medicine, Inc. Simultaneous extraction of DNA and RNA from FFPE tissues
HUE046489T2 (hu) * 2013-12-04 2020-03-30 Univ Texas Eljárás ráksejtekbõl származó exoszómák izolálására

Also Published As

Publication number Publication date
DK3076949T3 (da) 2019-11-25
JP7138372B2 (ja) 2022-09-16
EP3076949B1 (en) 2019-09-04
HUE046489T2 (hu) 2020-03-30
US10598665B2 (en) 2020-03-24
AU2014360344A1 (en) 2016-07-14
EP3076949A1 (en) 2016-10-12
AU2014360344B2 (en) 2018-11-29
HRP20192131T1 (hr) 2020-02-21
NZ721720A (en) 2022-04-29
WO2015085096A1 (en) 2015-06-11
US20200200755A1 (en) 2020-06-25
US20180045728A1 (en) 2018-02-15
CA2936100A1 (en) 2015-06-11
AU2019200573A1 (en) 2019-02-21
JP2021177760A (ja) 2021-11-18
EP3076949A4 (en) 2017-11-22
US20170059572A1 (en) 2017-03-02
JP2019198327A (ja) 2019-11-21
AU2019201290A1 (en) 2019-03-14
SI3076949T1 (sl) 2020-01-31
JP2017501694A (ja) 2017-01-19
US9921223B2 (en) 2018-03-20
ZA201604468B (en) 2024-01-31

Similar Documents

Publication Publication Date Title
HUE046489T2 (hu) Eljárás ráksejtekbõl származó exoszómák izolálására
GB201314695D0 (en) Method
GB201318465D0 (en) Method
GB201320351D0 (en) Method
GB201309057D0 (en) Method
GB201322851D0 (en) Method
GB201316744D0 (en) Method
GB201316849D0 (en) Method
GB201313249D0 (en) Method
GB201301857D0 (en) Method
GB201400320D0 (en) Method
GB201305714D0 (en) Method
GB201309654D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
GB201312609D0 (en) Method
GB201311389D0 (en) Method
GB201420652D0 (en) Method
PL2983923T3 (pl) Sposób wytwarzania paneli
GB201323087D0 (en) Method
GB201322768D0 (en) Method
GB201318830D0 (en) Method
GB201317826D0 (en) Method
GB201316878D0 (en) Method
GB201316321D0 (en) Method